Regeneronvs.United Therapeutics
REGN vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 3.0× larger than United Therapeutics by market cap; Regeneron trades at the lower P/E (15.7 vs 18.0); year to date, United Therapeutics leads (+12.3% vs −13.9%).
Side by side
| REGN | UTHR | |
|---|---|---|
| Market cap | $69.7B | $23.2B |
| Price | $664.52 | $547.06 |
| Today | −0.5% | −1.0% |
| Return YTD | −13.9% | +12.3% |
| Return 1Y | +18.7% | +82.3% |
| P/E | 15.7 | 18.0 |
| P/S | 4.7 | 7.3 |
| P/B | 2.2 | 3.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →More comparisons in Biotech & innovation
See where REGN and UTHR sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →